Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 12/20 | 0.50 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | CASP2 | P42575 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.41 |
| ▸ | ADH1C | P00326 | 1/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | ADH4 | P08319 | 1/20 | 0.41 |
| ▸ | ADH7 | P40394 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23945509 | 1.00 | EPHX1 (0.50) | EPHX1ZDHHC20ZDHHC2CASP2NAAA | |
| SCHEMBL20440154 | 1.00 | EPHX1 (0.50) | EPHX1ZDHHC20ZDHHC2CASP2NAAA | |
| SCHEMBL19380753 | 0.98 | EPHX1 (0.46) | EPHX1ZDHHC20ZDHHC2CASP2NAAA | |
| SCHEMBL19966745 | 0.91 | EPHX1 (0.41) | EPHX1ZDHHC20ZDHHC2ADH1BADH1C | |
| SCHEMBL26748968 | 0.88 | ALDH1A1 (0.48) | EPHX1ZDHHC20ZDHHC2CASP2ADH1B | |
| SCHEMBL24063876 | 0.82 | EPHX1 (0.45) | EPHX1ZDHHC20ZDHHC2CASP2NAAA | |
| SCHEMBL23945983 | 0.81 | KDM4E (0.33) | EPHX1 | |
| SCHEMBL21991783 | 0.81 | KDM4E (0.33) | EPHX1 | |
| SCHEMBL23945710 | 0.81 | KDM4E (0.33) | EPHX1 | |
| SCHEMBL20647303 | 0.81 | KDM4E (0.33) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EPHX1 1684/4885ZDHHC20 2303/4885ZDHHC2 2616/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPHX1 1684/4885ZDHHC20 2303/4885ZDHHC2 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.